Vol 27, No 1 (2022)
Review paper
Published online: 2021-11-05

open access

Page views 8065
Article views/downloads 1346
Get Citation

Connect on Social Media

Connect on Social Media

Doses, fractionations, constraints for stereotactic radiotherapy

Simona Borghesi1, Cynthia Aristei2, Francesco Marampon3
Rep Pract Oncol Radiother 2022;27(1):10-14.


This paper describes how to select the most appropriate stereotactic radiotherapy (SRT) dose and fractionation scheme according to lesion size and site, organs at risk (OARs) proximity and the biological effective dose. In single-dose SRT, 15–34 Gy are generally used while in fractionated SRT 30 and 75 Gy in 2–5 fractions are administered.

The ICRU Report No. 91, which is specifically dedicated to SRT treatments, provided indications for dose prescription (with its definition and essential steps), dose delivery and optimal coverage which was defined as the best planning target volume coverage that can be obtained in the irradiated district. Calculation algorithms and OAR dose constraints are provided as well as treatment planning system characteristics, suggested beam energy and multileaf collimator leaf size. Finally, parameters for irradiation geometry and plan quality are also reported.


Article available in PDF format

View PDF Download PDF file


  1. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
  2. Ahmed KA, Torres-Roca JF. Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. Cancer Control. 2016; 23(1): 21–29.
  3. Swaminath A, Chu W. Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions. Can Urol Assoc J. 2015; 9(7-8): 275–280.
  4. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000; 47(2): 291–298.
  5. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21): 2483–2491.
  6. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003; 124(5): 1946–1955.
  7. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013; 14(1): e28–e37.
  8. Yamamoto M, Serizawa T, Higuchi Y, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4): 387–395.
  9. Foote M, Bailey M, Smith L, et al. Guidelines for safe practice of stereotactic body (ablative) radiation therapy. J Med Imaging Radiat Oncol. 2015; 59(5): 646–653.
  10. Lax I, Blomgren H, Näslund I, et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994; 33(6): 677–683.
  11. Fowler JF, Tomé WA, Fenwick JD, et al. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys. 2004; 60(4): 1241–1256.
  12. ICRU Report 91, Prescribing, Recording, and Reporting of Stereotactic Treatments with Small Photon Beams. https://icru.org/content/reports/icru-report-91-prescribing-recording-and-reporting-of-stereotactic-treatments-with-small-photon-beams (3 January, 2021).
  13. Papiez L, Timmerman R, DesRosiers C, et al. Extracranial stereotactic radioablation: physical principles. Acta Oncol. 2003; 42(8): 882–894.
  14. Wu QJ, Wang Z, Kirkpatrick JP, et al. Impact of collimator leaf width and treatment technique on stereotactic radiosurgery and radiotherapy plans for intra- and extracranial lesions. Radiat Oncol. 2009; 4: 3.
  15. Ding M, Newman F, Chen C, et al. Dosimetric comparison between 3DCRT and IMRT using different multileaf collimators in the treatment of brain tumors. Med Dosim. 2009; 34(1): 1–8.
  16. Jin JY, Yin FF, Ryu S, et al. Dosimetric study using different leaf-width MLCs for treatment planning of dynamic conformal arcs and intensity-modulated radiosurgery. Med Phys. 2005; 32(2): 405–411.
  17. Monk JE, Perks JR, Doughty D, et al. Comparison of a micro-multileaf collimator with a 5-mm-leaf-width collimator for intracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 57(5): 1443–1449.
  18. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37(8): 4078–4101.
  19. Herfarth KK, Debus J, Krix M, et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys. 2000; 46(2): 329–335.
  20. Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Front Radiat Ther Oncol. 2004; 38: 100–105.
  21. Wulf J, Hädinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001; 177(12): 645–655.
  22. Hädinger U, Thiele W, Wulf J. Extracranial stereotactic radiotherapy: evaluation of PTV coverage and dose conformity. Z Med Phys. 2002; 12(4): 221–229.
  23. Hof H, Herfarth K, Münter M, et al. Stereotactic single-dose radiotherapy of stage I non–small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2003; 56(2): 335–341.
  24. Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004; 60(1): 186–196.
  25. Asbell SO, Grimm J, Xue J, et al. Introduction and Clinical Overview of the DVH Risk Map. Semin Radiat Oncol. 2016; 26(2): 89–96.
  26. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1): 109–122.
  27. Marks LB, Ten Haken RK, Martel MK, et al. Guest editor's introduction to QUANTEC: a user's guide, Int J Radiat Oncol Biol Phys. 2010; 76(3_Suppl): S1–S2.
  28. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008; 18(4): 215–222.
  29. 2020 NCCN guidelines. https://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf (3 January 2021).
  30. Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007; 25(8): 947–952.
  31. Murphy JD, Dieterich S, Chang DT, et al. Duodenal Toxicity in Single-fraction Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(3): S29–S30.
  32. Wersäll PJ, Blomgren H, Pisa P, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005; 77(1): 88–95.
  33. Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 76(3): 796–801.
  34. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24(30): 4833–4839.
  35. Quan K, Xu KM, Zhang Y, et al. Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma. Semin Radiat Oncol. 2016; 26(2): 112–119.
  36. Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol. 2009; 91(3): 360–368.
  37. Hiniker SM, Modlin LA, Choi CY, et al. Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery. Semin Radiat Oncol. 2016; 26(2): 97–104.
  38. Nuyttens JJ, Moiseenko V, McLaughlin M, et al. Esophageal Dose Tolerance in Patients Treated With Stereotactic Body Radiation Therapy. Semin Radiat Oncol. 2016; 26(2): 120–128.
  39. Kimsey F, McKay J, Gefter J, et al. Dose-Response Model for Chest Wall Tolerance of Stereotactic Body Radiation Therapy. Semin Radiat Oncol. 2016; 26(2): 129–134.
  40. Xue J, Kubicek G, Patel A, et al. Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels. Semin Radiat Oncol. 2016; 26(2): 135–139.
  41. Duijm M, Schillemans W, Aerts JG, et al. Dose and Volume of the Irradiated Main Bronchi and Related Side Effects in the Treatment of Central Lung Tumors With Stereotactic Radiotherapy. Semin Radiat Oncol. 2016; 26(2): 140–148.
  42. Goldsmith C, Price P, Cross T, et al. Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of Pancreatic Cancer: A Focus on Duodenal Dose Constraints. Semin Radiat Oncol. 2016; 26(2): 149–156.
  43. LaCouture TA, Xue J, Subedi G, et al. Small Bowel Dose Tolerance for Stereotactic Body Radiation Therapy. Semin Radiat Oncol. 2016; 26(2): 157–164.
  44. Grimm J, Sahgal A, Soltys SG, et al. Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord. Semin Radiat Oncol. 2016; 26(2): 165–171.
  45. Rashid A, Karam SD, Rashid B, et al. Multisession Radiosurgery for Hearing Preservation. Semin Radiat Oncol. 2016; 26(2): 105–111.
  46. Chao ST, Dad LK, Dawson LA, et al. ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy. Am J Clin Oncol. 2020; 43(8): 545–552.
  47. Saw C, Bao S, Li S. A review on the technical and dosimetric aspects of stereotactic body radiation therapy (SBRT). J Radiat Oncol. 2012; 1(4): 317–322.
  48. Hanna GG, McDonald F, Murray L, et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol). 2018; 30(1): 5–14.
  49. Schechter NR, Brown DW, Bovi JA, et al. ACR-ASTRO Practice Parameter for Communication: Radiation Oncology. Am J Clin Oncol. 2020; 43(8): 553–558.
  50. de Jong EEC, Guckenberger M, Andratschke N, et al. Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. Radiother Oncol. 2020; 142: 217–223.
  51. De Rose F, Franceschini D, Reggiori G, et al. Organs at risk in lung SBRT. Phys Med. 2017; 44: 131–138.
  52. Gerhard SG, Palma DA, Arifin AJ, et al. Organ at Risk Dose Constraints in SABR: A Systematic Review of Active Clinical Trials. Pract Radiat Oncol. 2021; 11(4): e355–e365.

Reports of Practical Oncology and Radiotherapy